WallStreetZenWallStreetZen

NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Stock

$43.38-0.73 (-1.65%)
Updated Apr 18, 2024
RARE Price
$43.38
Fair Value Price
N/A
Market Cap
$3.57B
52 Week Low
$31.52
52 Week High
$54.98
P/E
-5.26x
P/B
12.97x
P/S
8.1x
PEG
N/A
Dividend Yield
N/A
Revenue
$434.25M
Earnings
-$606.64M
Gross Margin
89.6%
Operating Margin
-140.12%
Profit Margin
-139.7%
Debt to Equity
4.41
Operating Cash Flow
-$475M
Beta
1.16
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RARE Overview

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RARE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RARE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RARE is poor value based on its book value relative to its share price (12.97x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
RARE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RARE due diligence checks available for Premium users.

Be the first to know about important RARE news, forecast changes, insider trades & much more!

RARE News

Valuation

RARE fair value

Fair Value of RARE stock based on Discounted Cash Flow (DCF)
Price
$43.38
Fair Value
$44.83
Undervalued by
3.23%
RARE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RARE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.26x
Industry
15.68x
Market
41.33x

RARE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
12.97x
Industry
5.76x
RARE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RARE's financial health

Profit margin

Revenue
$127.4M
Net Income
-$123.2M
Profit Margin
-96.7%
RARE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RARE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.5B
Liabilities
$1.2B
Debt to equity
4.41
RARE's short-term assets ($732.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RARE's long-term liabilities ($935.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RARE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RARE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$83.9M
Investing
-$107.0M
Financing
$330.6M
RARE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RARE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RARE$3.57B-1.65%-5.26x12.97x
INSM$3.68B-5.27%-4.64x-11.09x
BHVN$3.44B-4.25%-7.36x8.04x
IBRX$3.31B-6.30%-4.27x-5.64x
IOVA$3.27B-0.68%-6.20x5.60x

Ultragenyx Pharmaceutical Stock FAQ

What is Ultragenyx Pharmaceutical's quote symbol?

(NASDAQ: RARE) Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol RARE. Ultragenyx Pharmaceutical stock quotes can also be displayed as NASDAQ: RARE.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.

What is the 52 week high and low for Ultragenyx Pharmaceutical (NASDAQ: RARE)?

(NASDAQ: RARE) Ultragenyx Pharmaceutical's 52-week high was $54.98, and its 52-week low was $31.52. It is currently -21.1% from its 52-week high and 37.63% from its 52-week low.

How much is Ultragenyx Pharmaceutical stock worth today?

(NASDAQ: RARE) Ultragenyx Pharmaceutical currently has 82,335,687 outstanding shares. With Ultragenyx Pharmaceutical stock trading at $43.38 per share, the total value of Ultragenyx Pharmaceutical stock (market capitalization) is $3.57B.

Ultragenyx Pharmaceutical stock was originally listed at a price of $42.25 in Jan 31, 2014. If you had invested in Ultragenyx Pharmaceutical stock at $42.25, your return over the last 10 years would have been 2.67%, for an annualized return of 0.26% (not including any dividends or dividend reinvestments).

How much is Ultragenyx Pharmaceutical's stock price per share?

(NASDAQ: RARE) Ultragenyx Pharmaceutical stock price per share is $43.38 today (as of Apr 18, 2024).

What is Ultragenyx Pharmaceutical's Market Cap?

(NASDAQ: RARE) Ultragenyx Pharmaceutical's market cap is $3.57B, as of Apr 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Ultragenyx Pharmaceutical's market cap is calculated by multiplying RARE's current stock price of $43.38 by RARE's total outstanding shares of 82,335,687.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.